Moleculin Biotech’s (MBRX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Moleculin Biotech (NASDAQ:MBRX) in a research note issued to investors on Monday morning,Benzinga reports. They currently have a $8.00 target price on the stock.

Several other analysts have also commented on the stock. StockNews.com assumed coverage on shares of Moleculin Biotech in a research report on Thursday, March 13th. They issued a “sell” rating on the stock. Maxim Group cut shares of Moleculin Biotech from a “buy” rating to a “hold” rating in a report on Wednesday, February 12th.

Moleculin Biotech Trading Down 7.0 %

Shares of Moleculin Biotech stock opened at $1.07 on Monday. The business’s fifty day simple moving average is $1.32 and its 200 day simple moving average is $1.99. Moleculin Biotech has a 12 month low of $0.40 and a 12 month high of $6.23.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.